drugset / Trial / NCT03898791
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Timeline
- Start
- 2019-07-16
- Primary completion
- 2020-06-02
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK-01 | Unknown | — | Oral |